Analyze Key Developments Such as Regulation, Pricing & Reimbursement within the Pharmaceutical Market in Taiwan.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45467) has announced the addition of the Espicom Business Intelligence Ltd report: The Pharmaceutical Market: Taiwan to their offering.

Our in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Topics Covered
1. Executive Summary
 2. Pharmaceutical Market
 3. Key National Data Projections
 4. Geography
 5. Political Overview
 6. Economic Overview
 7. Population
 8. Demographic Indicators
 9. Mortality
 10. Morbidity
 11. Organisation & Administration
 12. Health Expenditure
 13. Hospital Services
 14. Ambulatory Care
 15. Medical Personnel
 16. Regulatory Environment
 17. Distribution Channels
 18. Pharmaceutical Imports
 19. Domestic Production & Exports
 20. Directory

Summary

Taiwan represents a major market for imported, advanced drugs, with per capita spending on pharmaceuticals among the highest in Asia.

Taiwan is a highly developed country, with a standard of living similar to much of southern Europe. As such, hospital services and staff are of high quality, although the latter are in short supply. Taiwan has a small domestic pharmaceutical industry; there are a large number of manufacturers, but they are almost always at the low end of the technology scale, concentrating on producing generics, OTC products and Chinese medicines.

Taiwan represents, therefore, a major market for imported, advanced drugs, with per capita spending on pharmaceuticals among the highest in Asia. It is, however, a difficult market. An opaque regulatory process and often highly discriminatory reimbursement practices make the market a challenging one in which to sell. These issues are currently under review although progress is unlikely to be swift. The burden of national health insurance debts is another area which the government must address and various cost-cutting measures may be enforced in the near future.

For more information visit http://www.researchandmarkets.com/reports/c45467